PMID- 22200806
OWN - NLM
STAT- MEDLINE
DCOM- 20130507
LR  - 20211021
IS  - 1437-160X (Electronic)
IS  - 0172-8172 (Linking)
VI  - 32
IP  - 12
DP  - 2012 Dec
TI  - Assessment of efficacy of pamidronate in undifferentiated spondyloarthropathy 
      (uSpA): a placebo control trial in a tertiary level center.
PG  - 3945-50
LID - 10.1007/s00296-011-2270-7 [doi]
AB  - Undifferentiated spondyloarthropathy (uSpA) is a nonspecific form of 
      spondyloarthropathy where nonsteroidal anti-inflammatory drugs (NSAIDs) and 
      disease-modifying anti-rheumatic drugs are still mainstay of treatment. We 
      evaluated the efficacy and adverse effect profile of pamidronate, in uSpA 
      patients refractory to NSAIDs therapy. A case series of 87 patients fulfilling 
      the modified Amor criteria for the diagnosis of uSpA, having active disease even 
      after 3-month continuous therapy with two NSAIDs, were selected. Active disease 
      was defined as a VAS score >50 in a scale of 0-100 in 3 out of four following 
      parameters: patients' global assessment, pain, BASFI and BASDAI morning 
      stiffness. Sixty-six patients among those were administered monthly pamidronate 
      infusion (60 mg over 4 h in 500 ml of normal saline) for 6 months. Other 21 
      patients (placebo group) transfused with normal saline. Treatment outcome was 
      assessed by comparing baseline and 6 months value of BASDAI, BASFI, BASMI, BAS-G, 
      CRP and ESR in both groups and improvement by ASAS-20 and BASDAI-50. Among the 66 
      patients, 48 patients (72.73%) achieved ASAS-20 and 42 patients (63.64%) achieved 
      BASDAI-50 response. Among the treatment group, mean ESR, CRP, BASDAI, BASFI, 
      BAS-G and BASAMI reduced by 54.81 mm/h (64.95%), 3.94 mg/l (43.3%), 3.74 
      (48.38%), 3.73 (49.40%), 4.47 (58.97%) and 4.28 (58.15%), respectively, after 
      treatment, whereas in placebo group, increased by 5.48 mm/h (6.34%), 0.34 mg/l 
      (3.77%), 0.24 (3.02%), 0.45 (6.03%), 0.05 (0.67%) and 0.52 (7.13%), respectively, 
      after 6 months. Intravenous pamidronate has very good efficacy for the treatment 
      of uSpA.
FAU - Sarkar, Rathindra Nath
AU  - Sarkar RN
AD  - Department of Medicine, Rheumatology Division, Calcutta Medical College, 88 
      College Street, Kolkata 700073, India. drrnsarkar09@gmail.com
FAU - Phaujdar, Sibaji
AU  - Phaujdar S
FAU - De, Dibyendu
AU  - De D
FAU - Bhattacharyya, Kuntal
AU  - Bhattacharyya K
LA  - eng
PT  - Controlled Clinical Trial
PT  - Journal Article
DEP - 20111227
PL  - Germany
TA  - Rheumatol Int
JT  - Rheumatology international
JID - 8206885
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Diphosphonates)
RN  - 0 (Placebos)
RN  - OYY3447OMC (Pamidronate)
SB  - IM
CIN - Rheumatol Int. 2013 Oct;33(10):2695. PMID: 22833238
MH  - Adult
MH  - Anti-Inflammatory Agents/*therapeutic use
MH  - Blood Sedimentation
MH  - Diphosphonates/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pain Measurement
MH  - Pamidronate
MH  - Placebos
MH  - Severity of Illness Index
MH  - Spondylarthropathies/*drug therapy
MH  - Treatment Outcome
EDAT- 2011/12/28 06:00
MHDA- 2013/05/08 06:00
CRDT- 2011/12/28 06:00
PHST- 2011/06/24 00:00 [received]
PHST- 2011/12/08 00:00 [accepted]
PHST- 2011/12/28 06:00 [entrez]
PHST- 2011/12/28 06:00 [pubmed]
PHST- 2013/05/08 06:00 [medline]
AID - 10.1007/s00296-011-2270-7 [doi]
PST - ppublish
SO  - Rheumatol Int. 2012 Dec;32(12):3945-50. doi: 10.1007/s00296-011-2270-7. Epub 2011 
      Dec 27.